Welcome to Epistem
Epistem is an established Biotechnology Company with headquarters in Manchester UK, and facilities in the US. Founded on ground-breaking research in epithelial stem cell biology, Epistem has evolved into a dynamic and successful enterprise enabling advances in medicine through the provision of innovative services and pioneering products. For over ten years Epistem has been providing a personalised service to customers worldwide, from virtual start-ups to established biotechnology enterprises, global pharmaceutical and personal care companies.
Company Overview
[+]
Contract Research
Committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline.
Pharmacogenomics
Specialists in gene expression and DNA genotyping, providing GCLP accredited services to drug development and diagnostic programs.
Genedrive
A pioneering Point-of-Care molecular diagnostic platform providing low cost, high sensitivity, next generation genotyping and sequence analysis in under 60 minutes.
Novel Therapies
Utilising Epistem's scientific heritage and expertise to identify key regulators of epithelial stem cell and develop novel therapeutics with implications in both oncology and regenerative medicine.
- News
- Events
- Annual Reports
- Careers
- Quality
CORRECTION FROM SOURCE: Indian Approval of Import Licence for Genedrive(R) TB Molecular Diagnostic Test
Thursday April 23, 2015
CORRECTION FROM SOURCE: Indian Approval of Import Licence for Genedrive(R) TB Molecular Diagnostic Test MANCHESTER, UNITED
Epistem and CRT Announce Agreement for the Use of Patient Derived Leukemic Samples
Tuesday April 21, 2015
Epistem and Cancer Research Technologies announce agreement for the use of leukemia Primagrafts MANCHESTER, UNITED KINGDOM--(Marketwired
Epistem Announces the Successful Evaluation of New RNA-AMP(TM) (RNA-Amplification) Technology
Thursday February 12, 2015
MANCHESTER, UNITED KINGDOM--(Marketwired - Feb 12, 2015) - Epistem Holdings Plc (EHP.L), the Personalised Medicine and
Successful Completion of Genedrive(R) Indian Clinical Trials and Regulatory Submission
Tuesday October 28, 2014
LONDON, UNITED KINGDOM -- (Marketwired) -- 10/28/14 -- Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology
Next Event
12th World Congress on Inflammation
8th Aug - 12th Aug
Boston, MA
Coming Up
Next Generation Dx Summit 2015
18th Aug - 20th Aug
Washington DC
Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers
Wednesday July 15, 2015
New test could predict arthritis drug failure in patients
Monday July 13, 2015
Congratulations to Epistem on the 2015 best Innovation Technology award for Genedrive
Friday June 26, 2015
Anti TNF-alpha treatment increases circulating Th17 cells in different types of inflammatory arthritis
Thursday June 25, 2015
BillGates: What’s the secret to a better test? Competition: via
Tuesday June 16, 2015

Epistem releases Annual Report & Accounts to 30th June 2014.
View Annual Report.
Could you help Epistem provide specialist expertise and analyses on epithelial tissue and adult stem cells to the ever demanding biotechnology and pharmaceutical industry?
If you are interested in a career with Epistem, contact us today with your details. Email your CV/resume to jobs@epistem.co.uk
Epistem strives to become a world class biotechnology and personalised medicine company applying its expertise to all services provided. Epistem aims to improve services and treatments provided by the Healthcare industry.
Epistem is committed to ensuring accurate and timely provision of superior products and services and to continuously meet or exceed the stated or implied expectations of our customers.
Epistem is committed to the continuous improvement of its Quality Management System and compliance with the relevant regulatory requirements.










This site uses cookies for tracking and statistical purposes. Please read our 